TD Cowen Maintains Buy on AVITA Medical, Raises Price Target to $14
TD Cowen analyst Joshua Jennings maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $12 to $14.
Read original at benzingaStocks · News reference
AVITA Medical shares are trading higher after the company announced its PermeaDerm-I study met primary endpoint, delivering clinically comparable outcomes to cadaveric allograft with 70% cost reduction.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 18, 2026, 5:19 PM
- Checked
- Aug 18, 2026, 5:19 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
BTIG Maintains Buy on AVITA Medical, Raises Price Target to $11
BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $7 to $11.
Read original at benzingaAVITA Medical Announces PermeaDerm-I Study Met Primary Endpoint, Delivering Clinically Comparable Outcomes To Cadaveric Allograft With 70% Cost Reduction
Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001) 96% reduction in preparation time and comparable clinical
Read original at benzinga